Skip to Main Content

389

Views

0

CrossRef citations to date

0

Altmetric

Musculoskeletal

The cost-effectiveness of a bimekizumab versus IL-17A inhibitors treatment-pathway in patients with active axial spondyloarthritis in Scotland

Michael F. Mørupa UCB Pharma, Copenhagen, DenmarkView further author information

,

Vanessa Taiebb UCB Pharma, Colombes, FranceView further author information

,

Damon Willemsc UCB Pharma Brussels, BelgiumView further author information

,

Micah Rosed UCB Pharma, Slough, UKView further author information

,

Nikos Lyrisd UCB Pharma, Slough, UKView further author information

,

Mark Lamottee Th(is)Modeling, Asse, BelgiumView further author information

,

Laetitia Gerlierf IQVIA, Zaventem, BelgiumCorrespondence[email protected]

https://orcid.org/0000-0003-0061-0194 View further author information

&

Howard Thomg University of Bristol, Bristol, UK;h Clifton Insight, Bristol, UKView further author information